AT1 FY21 - General Discussion + FA, page-1705

Hiya, I was posting media articles in LDX thread (post-FY21 results related)...

I wanted to highlight something that has been mentioned by LDX mgmt - re: US FebriDx market

You can read the whole article here – Post #: 55806346 - its mostly a summary of LDX results + company history + ann'd goals

This is the last para:

This goal of getting US health dept reimbursements for FebriDx test seems significant to me (if they can get this, whether professional use or consumer self-test costs).

Its just as significant as Ag RDTs being asked to be subsidised via Medicare in AU market. The US diagnostics market is already very accepting of POCTs, self-tests etc & of course a far larger size. Above goal, if successful, would allow US consumer + professional use take-up at far higher rates, than if it was left to a consumer-pays approach (especially in US market where there is no 100% universal healthcare coverage etc and certain society levels do avoid GP visits and tests unless absolutely necessary due to the out of pocket costs).

If this occurs, it would potentially result in much higher LDX revenues and naturally flow-on AT1 OEM revenue. Something to watch and note as US events unfold for LDX.